指南与共识头痛与眩晕

成人偏头痛预防药物治疗的系统综述:AAN指南小组委员会与美国头痛学会报告

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society.
指南 / 共识 · Neurology · 2026-08-31

本系统综述评估成人发作性和慢性偏头痛的药物预防治疗,纳入217项随机对照试验,采用GRADE分级证据确定性。高确定性证据支持galcanezumab和erenumab减少发作性偏头痛频率,以及fremanezumab、galcanezumab和onabotulinumtoxinA减少慢性偏头痛频率;多种药物显示中或低确定性获益。

要点

  • 发作性偏头痛:galcanezumab和erenumab高确定性减少头痛频率。
  • 慢性偏头痛:fremanezumab、galcanezumab和onabotulinumtoxinA高确定性减少头痛频率。
  • 多种CGRP靶向药物及托吡酯、onabotulinumtoxinA改善患者报告生活质量。

核心结论

  • 高和中确定性证据证实多种已确立和新型预防药物治疗成人发作性和慢性偏头痛有效。
  • 多种药物在验证性量表上改善患者报告的生活质量结局。

研究设计与样本

  • 多学科小组按照2017年AAN临床实践指南过程手册进行系统综述。
  • 纳入评估成人发作性或慢性偏头痛药物预防治疗的随机对照试验。
  • 检索MEDLINE、Embase和ClinicalTrials.gov从建库至2024年6月6日。
  • 共217项研究符合纳入标准,采用改良GRADE分级证据确定性。

主要发现

  • 发作性偏头痛:高确定性证据显示galcanezumab和erenumab减少头痛频率优于安慰剂。
  • 发作性偏头痛:中确定性证据支持atogepant、eptinezumab、fremanezumab、propranolol、topiramate和valproate获益。
  • 发作性偏头痛:amitriptyline、bisoprolol、flunarizine、fluoxetine、levetiracetam、metoprolol、nifedipine、pizotifen和telmisartan有低确定性证据提示可能获益。
  • 慢性偏头痛:高确定性证据支持fremanezumab、galcanezumab和onabotulinumtoxinA减少头痛频率。
  • 慢性偏头痛:中确定性证据支持atogepant、eptinezumab、erenumab、topiramate和valproate获益。

临床怎么用

  • 证据结论用于制定循证推荐,指导临床医生为成人发作性和慢性偏头痛选择预防药物。

局限性

  • 活性药物比较证据有限且置信度低或极低,限制比较有效性结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: This systematic review (SR) provides updated evidence-based conclusions regarding the use of pharmacologic migraine prevention in adults to inform a new joint American Academy of Neurology (AAN) and American Headache Society practice guideline. METHODS: A multidisciplinary panel conducted an SR following the 2017 AAN Clinical Practice Guideline Process Manual. Randomized controlled trials evaluating pharmacologic preventive treatments for adults with episodic or chronic migraine were included. Searches encompassed MEDLINE, Embase, and ClinicalTrials.gov from database inception through June 6, 2024. Studies were screened in duplicate, with dual independent risk-of-bias assessment. Outcomes included change in monthly headache days, ≥50% responder rate, and validated patient-reported quality of life (QOL) measures. Raw mean differences, standardized mean differences, and risk ratios were calculated. A modified Grading of Recommendations Assessment, Development, and Evaluation process was used to classify certainty of evidence. RESULTS: A total of 217 studies met inclusion criteria. For episodic migraine, high-confidence evidence showed that galcanezumab and erenumab are more effective than placebo in reducing headache frequency. Moderate-confidence evidence supported benefit from atogepant, eptinezumab, fremanezumab, propranolol, topiramate, and valproate. Several additional oral agents including amitriptyline, bisoprolol, flunarizine, fluoxetine, levetiracetam, metoprolol, nifedipine, pizotifen, and telmisartan had low-confidence evidence suggesting possible benefit. For chronic migraine, high-confidence evidence supported reductions in headache frequency with fremanezumab, galcanezumab, and onabotulinumtoxinA. Moderate-confidence evidence supported benefit from atogepant, eptinezumab, erenumab, topiramate and valproate. Across both episodic and chronic migraine populations, erenumab, fremanezumab, galcanezumab, eptinezumab, rimegepant, atogepant, topiramate and onabotulinumtoxinA demonstrated improvements in patient-reported QOL outcomes on validated instruments. Evidence comparing active treatments was limited and generally of low or very low confidence, restricting conclusions about comparative effectiveness. DISCUSSION: This SR provides a comprehensive synthesis of evidence on pharmacologic migraine prevention in adults. High- and moderate-confidence findings confirm the efficacy of several established and newer preventive therapies and demonstrate improvements in patient-reported outcomes across multiple validated measures. These conclusions informed the development of evidence-based recommendations, presented in a companion publication, to guide clinicians in selecting preventive medications for adults with episodic and chronic migraine.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Pringsheim T, Smith DB, Tanveer S, et al. Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society. Neurology. 2026. PMID: 42673559. doi:10.1212/WNL.0000000000218112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。